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Abstract:  Despite  the  recent  trend  toward  a  slight  decrease  in  age-adjusted  cancer 
mortality in some countries, crude mortality rates will continue to increase, driven by the 
demographic  shift  towards  an  aged  population.  Small  molecules  (small  molecules  and 
biologics) are not only a new therapeutic acquisition, but the tools of a more fundamental 
transition: the transformation of cancer from a rapidly fatal disease into a chronic condition. 
Antibodies and cancer vaccines can be used  for a long time, even beyond progressive 
disease, and in aged patients, usually unfit for more aggressive conventional treatments. 
However, this transition to chronicity will require novel developmental guidelines adequate 
to this kind of drugs, for which optimal dose is not usually the maximal tolerated dose, 
pharmacokinetics does not define treatment schedule, and tumor shrinkage is not a good 
correlate  of  survival.  The  ongoing  cancer  immunotherapy  program  (including  several 
monoclonal antibodies and therapeutic vaccines) at the Centre of Molecular Immunology 
can  illustrate  the  issues  to  be  addressed,  both  biological  and  social,  along  the  path  to 
transform  advanced  cancer  into  a  chronic  non-communicable  disease  compatible  with 
years of quality life. 
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1. Introduction: The Increasing Burden of Advanced Cancer 
For  decades,  scientific  community  has  been  obsessed  in  finding  a  cure  for  cancer.  Modern 
therapeutic  technologies  have  in  fact  produced  cures,  especially  in  early  stage  tumors;  and  the  
fraction  of  the  incidence  which  can  be  diagnosed  in  early  stage  has  been  increased  by  improved  
diagnostic technologies. 
These technological advances, together with the simultaneous decrease in cigarette smoking, have 
started to translate, in the last 20 years, into a slight decline in age-adjusted mortality rates. Although 
the epidemiological landscape varies among different countries, the basic trends are best observed 
where detailed statistics in hundred million size populations are available. In the US, death rates from 
all cancers peaked in 1990 for men and 1991 for women, showing then a decreasing trend of 1.3%/year 
for men and 0.5%/year in women [1]. In Europe, the mortality rate is declining in some countries, but 
increasing in others [2]. 
This  trend  toward  decreased  cancer  mortality  is  emerging  just  in  some  industrialized  nations. 
Among  the  7.9  millions  of  cancer  related  deaths  occurring  worldwide  in  2007,  70%  occurred  in 
developing countries, where mortality continues to increase, cancer is diagnosed late, and the rate of 
cancer survival is very low. 
Nevertheless, the fact that the age-adjusted cancer mortality rate for all tumors, and particularly for 
some of them is decreasing in some countries, shows that this goal is, at least technically reachable. 
Although  these  achievements  have  received  strong  publicity  and  elicited  justified  optimism,  it 
should  not  be  forgotten  that  the  age-adjusted mortality  rate  was  what  declined  and  not  the crude 
mortality  rate.  The  slight  decrease  of  the  cancer  mortality  rate  within  each  group  of  ages  is 
counterbalanced by the demographic trend to an increase in the percentage of population in older age 
groups. Worldwide the number of cancer deaths per year continues to increase, having doubled in the 
past 30 years, and it is expected to rise to 17 million by 2030 [3]. Every year, more people die from 
cancer than from AIDS, tuberculosis and malaria all combined. 
The increase in human life expectancy has a second, less noticed, effect on cancer mortality, for the 
group of patients already diagnosed and apparently cured. This effect comes from the fact that the 
transition from the disease-free interval (after primary treatment) to the actively progressing disease 
has probabilistic first grade kinetics [4]. With the delay of mortality from all other causes combined, 
many successfully treated patients will live more time, at a constant probability rate to relapse. 
In addition to the bigger incidence of advanced cancer, the trend towards an increased survival after 
the  disease  became  advanced,  will  cause  an  increase  in  the  prevalence  (incidence  x  survival)  of 
patients bearing advanced cancer. 
The overall conclusion is that, no matter what we could advance in primary prevention and early 
diagnosis, we should expect an increasing burden of advanced cancer in the foreseeable future to be 
assisted by Public Health Systems. To face this challenge, the significant statistics are prevalence and 
crude mortality rate, not age-adjusted rate. 
Another dimension of the challenge is the prevalence of co-morbidities. The median age of cancer 
diagnosis is increasing and it has been projected that 70% of all neoplasms will occur in individuals  
of 65 years and older by 2030 [5]. Within this age group, there is more than 40% probability to  
find  hypertension  and  heart-related  diseases  [6].  As  many  as  25%  of  65–69  years  old  and  50%  Int. J. Environ. Res. Public Health 2011, 8                 
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of 80–84 years old, are affected by two or more chronic health conditions simultaneously [6]. Many of 
these patients will not be eligible for the current aggressive treatments now considered ―state-of-the-art‖ 
in Oncology [7]. 
2. The Emerging Evidence of a Transition to Chronicity 
Overall  figures  of  incidence  and  mortality  usually  blurry  the  particular  epidemiology  of  the 
―advanced disease‖. The improvement in the long term survival rate of cancer patients reflects the 
combined effects of earlier diagnose, better therapeutic technology for the loco-regional disease and 
finally,  better  outcome  of  the  advanced  disease.  Trends  in  mortality  rates  mix  also  the  effect  of 
changes in primary incidence due to prevalence variation of risk factors such as tobacco smoking.  
There are scarce population-based data on survival and mortality once the disease became systemic. 
Nevertheless, although there is a therapeutic stagnation in some tumors, for several others, survival is 
increasing inside this stage of the clinical course. 
Recent data from the US National Cancer Institute [1] indicates that for already diagnosed cancers 
with distant dissemination, 5-year survival is 27% for female breast, 28% for oral cavity & pharynx,  
31% for ovary, 32% for prostate. Analogous data in Cuba shows 5-year survivals of 30% for female 
breast, 32% for uterine corpus, 24% for oral cavity and 20% for colon [8-10]. A similar picture is 
emerging for recurrent cancer. A study of five successive cohorts of patients recurring in 1974, 1980, 
1985, 1990 and 1995 shows a continuous trend to a better survival [11,12]. 
These trends in advanced cancer survival do not contain the effects of improvements on primary 
prevention, early diagnosis or disease treatment. They should be interpreted as improvements in the 
systemic  treatment  of  the  disseminated  disease.  Moreover,  better  overall  survival  of  patients  with 
leukemia,  lymphoma,  testicular  cancer  and  stage  II–III  breast cancer,  is  not  attributable  to  earlier 
diagnosis but to therapeutic technologies (including prognostic stratification techniques).  
With modern therapies, many patients are more likely to die with cancer than of it. The transition 
from a rapid fatal disease to a chronic condition, compatible with many years of quality life, is not new 
in the history of Medicine. It is exactly what happened with diabetes mellitus after the discovery of 
insulin  in  1921.  Formerly  described  as  a  form  of  death,  rather  than  as  a  chronic  disease,  insulin 
treatment allowed the survival extension by the middle of the XX century. A series of technological 
improvements (slow insulin, oral drugs, portable glucose meters, insulin sensitizers) ended in 1993 
with the report of the ―Diabetes Control and Complication Trial‖ which demonstrated that intensive 
therapy  delays  the  onset  and  progression  of  long  term  complications  in  individuals  with  type  1  
diabetes [13].  
Analogous  histories  could  be  described  for  cardiovascular  diseases,  kidney  failure,  chronic 
respiratory diseases and other conditions, which as well as advanced cancer, cannot be cured, but can 
be  controlled  for  many  years.  The  main  target  of  intelligent  human  intervention  in  chronic  
non-communicable diseases is not cure, but control, which means slow progression, and prevention or 
delay of complications. 
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3. Building the Tools: The Role of Biologics and Small Molecules 
Which could be the tools of that intervention? Cytotoxic chemotherapy was a major advance in 
cancer treatment. Introduced by the middle of XX-century through first generation alkylating agents 
and  anti-metabolites,  it  has  been  improved  along  six  decades  with  an  increasing  arsenal  of  new 
antitumor drugs, drug combinations, and support treatments. Chemotherapy made a major contribution 
to  the  cure  rate  of  hematological  malignancies,  testicular  cancer  and  a  few  other  tumors,  and 
contributed to increased survival in many others. But, for survival effect to translate into mortality rate 
reduction, the improvement should be large enough to allow the intervention of competing causes of 
death,  however,  such  long  term  effect  would  require  long  term  treatments,  which  cannot  be 
implemented with cytotoxic chemotherapy. 
With  the  exception  of  anti-hormone  treatments  for  breast  and  prostate  cancers,  the  therapeutic 
arsenal  of  medical  oncology  has  lacked,  until  very  recently,  low  toxicity  drugs  suitable  for  long  
term use. 
Two major acquisitions are changing this landscape: small molecules and biologics. 
Both, small inhibitors and biologics have shown activity in combination with chemotherapy and 
radiation but also as monotherapy. Cancer‘s ‗addiction‘ to oncogenes is sometimes so strong that even, 
brief inactivation of a single oncogene can cause a dramatic and sustained response. The big challenge 
consists is identifying the population that can be susceptible to each treatment with a simple test. 
Although there is a wide overlap between small molecules and biologics, we will discuss them 
separately, for the sake of clarity. 
The  first  flow  of  therapeutic  improvements  comes  from  the  introduction  of  small  molecules 
targeting specific intracellular receptors, which have had a considerable impact on the management of 
several  neoplastic  diseases,  such  as  gastrointestinal  stromal  tumors,  hepatocellular  and  renal  cell 
carcinomas. For chronic myelogenous leukaemia or gastrointestinal stromal tumours (GIST), imatinib 
(Gleevec), a tyrosine kinase inhibitor that targets platelet-derived growth factor receptor, KIT, and the 
BCR-ABL  oncoprotein  [14,15],  is  remarkably  effective  in  providing  long-term  control.  Sunitinib 
(Sutent) and sorafenib (Nexavar) are small inhibitors that target vascular endothelial growth factor 
receptor, platelet-derived growth factor receptor, C-Kit and others. Antitumor activity has been shown 
in renal cell carcinoma for sunitinib as first-line treatment and for sorafenib, as second-line. In addition, 
sunitinib  is  approved  as  second-line  therapy  for  patients  with  GIST  refractory  to  imatinib  while 
sorafenib  has  resulted  in  a  significant  prolongation  of  survival  in  patients  with  hepatocellular 
carcinoma [16]. Still, two other agents have been approved for the second-line treatment of lung cancer 
(NSCLC): erlotinib (Tarceva) and gefitinib (Iressa), which can produce a dramatic response in those 
subjects with activating mutations of the Epidermal Growth Factor Receptor (EGFR) [17,18].  
The second flow of therapeutic improvements comes from the so called Biotechnology Revolution. 
What  it  means,  is  that  the  development  of  recombinant  DNA  techniques,  modern  high  scale 
fermentation and purification technologies, has allowed us to obtain and produce biological molecules 
with  the  same  purity,  scalability  and  reproducibility  of  synthetic  chemistry  pharmaceuticals.  The 
potential diversity of biological molecules is mind-boggling. Looking only at antibodies, a human 
being can have more than a billion different molecules, and the introduction of point mutations at will, Int. J. Environ. Res. Public Health 2011, 8                 
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could even increase that figure by several orders of magnitude. Potential pharmaceutical applications 
are very diverse, but up to now, the main target of Biotechnology has been cancer treatment.  
Starting with Interferon alpha, registered in 1995 for malignant melanoma, 16 biologics have so far 
entered into the market for cancer treatment, including 10 monoclonal antibodies [19], and the first 
therapeutic vaccine for prostate cancer in 2010 [20]. 
The last published survey of the Pharmaceutical Manufacturers Association of America shows 633 
biologics in development. Out of these, 254 are being developed for cancer treatments, including 109 
monoclonal antibodies and 63 vaccines [21]. Assuming that just one third of these drugs, will enter 
into the market, we could expect more than 80 new biologics for treating cancer in the near future [21]. 
Currently the monoclonal antibodies which target the CD20 molecule (rituximab), the Epidermal 
Growth Factor Receptor (cetuximab), the HER-2 receptor (trastuzumab), and the Vascular Endothelial 
Growth Factor (bevacizumab) are already among the 10 top-selling drugs [22]. 
The contribution of monoclonal antibodies for the treatment of cancer is not just because they 
enlarge the arsenal of choices. They are also a different kind of drugs. Their toxicities (although not 
inexistent) are much lower than those of classic cytostatics, and there is emerging evidence of the 
benefit of their long term use, even beyond the progression of the disease [23,24]. 
Antibodies can also be used in elderly or frail patients who are unfit for chemotherapy. These are 
precisely the properties required for a therapeutic tool to be instrumental in the transition of advanced 
cancer to a chronic disease. Moreover, there is a huge potential of combining monoclonal antibodies 
and vaccines with conventional chemotherapy and radiation regimes.  
Chemotherapy  and  immunotherapy  were  first  considered  to  be  non-compatible,  because  of  the 
immunosuppressive  effect  of  cytotoxic  drugs.  However,  more  recent  evidence  is  suggesting  that 
chemotherapy could in fact stimulates antitumor immunity through diverse mechanisms such as the 
induction  of  immunogenic  apoptosis,  the  opening  of  homeostatic  space  (lymphopenia)  for  the 
expansion of antitumor lymphocyte clones, and the inhibition of the regulatory loops of the immune 
system (regulatory T-cells and myeloid-derived suppressor cells [25-27]. Combinations of biologics 
with some chemotherapies at low doses, could also be evaluated as therapeutic regimes amenable to 
chronic use [28,29]. 
4. Using the Tools: The Changing Paradigm in Clinical Research 
The old and widely accepted paradigm for oncology drug development was based on the experience 
of classical cytotoxic agents. Currently accepted concepts on chemotherapy were built in the 70s based 
on experiments on transplantable tumors in mice and on the early experiences of successful trials 
mainly in hematological malignancies. These concepts were later extended to solid tumors, without the 
same success rate. Most cancer pharmacologists would accept that antitumor activity is connected to 
toxicity and therefore, treatments must be scaled up to maximal tolerated dose (to be found in Phase I 
clinical trials); that pharmacokinetics is relevant to define the optimal schedule; that an active drug 
should produce a rapid tumor shrinkage; that response rate is a predictor of survival; and that tumor 
progression indicates treatment failure. However, the unique characteristics of small molecules and 
biologics challenge these dogmas and demand novel developmental guidelines. For these new drugs 
the optimal biologic dose can be far below the maximal tolerated dose, mechanisms of action can be Int. J. Environ. Res. Public Health 2011, 8                 
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indirect and therefore not directly related to pharmacokinetics, effect in survival can be seen without 
tumor shrinkage and therapeutic effect could be delayed in time and continue beyond progression. 
Accordingly, a new paradigm for drug development is emerging after the introduction of these new 
molecules in the clinic [30-33]. This emerging paradigm aims at finding the optimal biologic dose in a 
―proof of principle trial‖ according to some pre-defined biological endpoint or biomarker; followed by 
an  efficacy  assessment  in  a  randomized  trial  with  long  term  treatment  and  survival  as  the  main 
endpoint. Efficacy trials could test drug combinations directly and their statistical design should take 
into account the possibility of delayed separation of survival curves.  
The  current  approach  for  drug  development  has  other  limitations.  As  per  the  statistics,  as  few  
as 2% to 3% of cancer patients are enrolled in clinical trials [34]. This accrual is not representative of 
the general population, since trials impose very restricted inclusion criteria. For example, older patients 
are  underrepresented  in  clinical  trials,  yet  approximately  two-thirds  of  patients  diagnosed  with  
non-small cell lung cancer are older than 65 years, and nearly 50% are older than 70 years. In a  
meta-analysis of patients recruited in clinical trials, only 17% were over 70 years old [35].  
As  a  consequence,  the  results  of  the  clinical  trials  might  not  be  reproduced  in  the  real cancer 
population [36,37]. Randomized clinical trials provide internal validity, yet, whether benefits/safety 
extend  to  the  general  population  often  remain  unknown.  Well  designed  population  studies  would 
provide unique insights into the generalization and societal benefits of treatment in the real world. 
Considering its unique safety profile, it would be feasible to conduct population based studies with 
small inhibitors or biologics. 
5. Case Study: The CIM-Immunotherapy Program 
There are not many organizations conducting fundamental immunology research, clinical trials and 
biotechnology  manufacturing  at  the  same  time.  There  are  not  many  organizations  developing 
proprietary monoclonal antibodies and therapeutic vaccines at the same time. The Centre of Molecular 
Immunology (CIM) is one of them. It is an organization with a staff of 1,000 people located in the west 
Havana Biotechnology Pole in Cuba [38]. The comprehensiveness of the CIM program, its tight links 
with the National Cancer Program, and the simultaneous priority of the development of Primary Health 
Care and Biotechnology Industry [38], create a favorable perspective to evaluate how Biotechnology 
could be instrumental for the transition of advanced cancer into a chronic disease, and the current 
balance of opportunities and difficulties. 
In its 15 years of operation CIM has built a 24 project pipeline including biosimilar molecules such 
as  recombinant  Erythropoietin,  Granulocyte  Colony  Stimulating  Factor,  antiCD20  and  anti-HER2 
monoclonal antibodies, together with proprietary monoclonal antibodies and cancer vaccines.  
Its new product development pipeline, although diverse, concentrates around three main targets: 
The  Epidermal  Growth  Factor  Receptor  (EGFR)  system,  the  cell  membrane  gangliosides  and  the 
regulatory loops of the immune system. 
Two  of  the  proprietary  products  have  already  transited  through  clinical  trials  and  received 
registration in several countries: the anti-EGFR humanized monoclonal antibody nimotuzumab [39-41] 
and  the  EGF  conjugated  therapeutic  vaccine  CimaVax-EGF  [42,43].  Two  other  proprietary 
monoclonal antibodies, the 14F7 anti-ganglioside antibody [44] for breast cancer and the anti-CD6 Int. J. Environ. Res. Public Health 2011, 8                 
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antibody (itolizumab) for autoimmune diseases [45], together with two new therapeutic vaccines, the 
N-glycoylganglioside vaccine for breast cancer [46] and the racotumumab anti-idiotype antibody for 
lung cancer, are currently in clinical testing [47]. 
Product  development  has  followed  the  classic  paradigm  of  pre-clinical  pharmacology,  phase  
I–II–III clinical trials and regulatory clearance. However, the clinical experience with these products 
illustrates three fundamental concepts which are pivotal for the transition of advanced cancer into a 
chronic disease: chronic use, combinations, and primary care involvement. 
The  humanized  monoclonal  antibody  nimotuzumab  has  shown  so  far  antitumor  activity  
(combined with chemo-radiation) in head and neck [40,41,48], brain [49,50] and esophageal cancer 
(unpublished results). It is currently being tested in 25 clinical trials, ongoing in 12 countries, for other  
tumor localizations. 
It has a very good safety profile, basically devoid of skin toxicity which is a limiting toxicity for 
other anti-EGFR drugs [51,52]. This property has allowed long term use of nimotuzumab, even in 
pediatric population. More than 450 patients have received bi-weekly treatment for 1 year or more,  
and 135 for more than 2 years. Drug related adverse events (grade 1 or 2 toxicity in 15–20% of cases) 
have shown the same probability of manifestation in the first doses and after 1 year of treatment, 
indicating the lack of cumulative toxicity. 
The CimaVax-EGF therapeutic vaccine has provided survival advantage in advanced non-small cell 
lung cancer. The survival effect is related to the anti-EGF immune response, and to the decrease of 
seric EGF concentration [43]. Immunogenicity is improved after using a combined schedule, before 
and after chemotherapy [53].  
Again, long term vaccination is very well tolerated. More than 50 advanced lung cancer patients 
have received monthly vaccinations for more than 1 year, without evidence of cumulative toxicity. 
Moreover, continuous vaccination increased the probability of obtaining high anti-EGF antibody titers, 
a response which is correlated with survival [54].  
Both, antibody and vaccine long term use is compatible with administration in the primary care 
setting. A continuous care program in selected policlinics has been recently launched for the treatment 
of advanced lung cancer after termination or failure of first line chemotherapy, aiming to integrate 
immunotherapy, nutritional support and pain control. 
6. The Obstacles Along the Road 
The road to convert advanced cancer into a chronic disease compatible with years of quality life 
using the tools of biotechnology will face obstacles at three levels. Two of them are operational. The 
third is rooted in the fundamental biology of the interaction between the immune system and the tumor. 
The first operational problem is how to prepare the health system to efficiently manage a growing 
number of patients with advanced cancer, who will require long duration and complex assistance, but 
who will be ambulatory and socially integrated. Most modern public health systems emerged at the 
moment when the control of infectious diseases and maternal and child care were the challenges to 
face. They are not well prepared for the management of chronic diseases [55,56]. In the control of 
infectious  diseases  and  the  reduction  of  infant  mortality  there  are  a  handful  of  highly  protagonic 
interventions  producing  major  impact  at  population  level  (preventive  vaccinations,  antibiotics, Int. J. Environ. Res. Public Health 2011, 8                 
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institutional childbirth, maternal lactation, safety of water, availability of rehydration treatments). The 
management of chronic non-communicable diseases on the other hand, requires complex and long 
interventions including diverse components, none of which produce high impact in isolation [57]. In 
the  particular  case  of advanced  cancer,  anticancer  drugs  should  be  integrated with  an  appropriate 
palliative care including nutritional support and pain control [58]. About 60% of advanced cancer 
patients experience several kinds of dysfunction as well as moderate to severe pain requiring opioids. 
If novel anticancer drugs will slow the progression of the disease and prolong life, then, quality of life 
becomes a major goal.  
A new kind of medical research will be needed, that goes beyond the conventional clinical trial 
methodology, to evaluate several interventions simultaneously, as a package, for survival and quality 
of life in unselected patient populations. 
The second operational problem is manufacturing and costs. Chronic use of biologics in many 
patients at primary care level will be impossible with the current costs, which are at odds with the 
worldwide concern on escalating health expenditures [59,60]. A major component of this problem, 
which is beyond the scope of this article, is health economics, and the current debate about who pays 
for  what.  Another  component  is  manufacturing  capacity.  Monoclonal  antibodies  (and  also  some 
vaccines)  are  produced  through  mammalian  cell  fermentation,  a  technology  demanding  big 
investments. Just for the currently most used antibodies (targeting CD20, EGFR, HER2 and VEGF) at 
the existing dosages  and  schedules, and  taking into account  the prevalence of their  indications,  a 
demand of 2 kg per million inhabitants can be calculated. This translates into a worldwide demand of 
more than 10,000 kg of monoclonal antibodies, only for cancer treatment (not including other uses like 
autoimmune diseases). The installed manufacturing capacity in the few countries using this technology 
is currently less than 3,000 kg. Huge industrial investments or major advances in the efficiency of the 
process, or both, will be required. 
Beyond these operational obstacles, there are also several basic biology problems to be addressed. 
Three of them worth to be mentioned here: the first is the size and duration of the immune response. 
The immune system has been selected by evolution for fast but short term response to an invading 
pathogen.  It  is  endowed  with  diverse  mechanisms  of  programmed  contraction  of  the  response. 
Therapeutic  cancer  vaccines  will  require  long  lasting  immune  effectors.  Probably,  these  effectors 
would be also required by monoclonal antibodies whose antitumor activity is partially dependent on 
the mobilization of cellular  immunity [61]. Chronic  immunotherapy will need the  combination of 
monoclonal antibodies and therapeutic vaccines with drugs acting on the redundant regulatory loops  
of  the  immune  system.  Several  clinical  trials  of  this  kind  of  combination  are  emerging  in  the  
literature [62,63]. 
The  second  is  senescence.  The  Homo  sapiens  species  evolved  during  150,000  years  in  a  high 
mortality environment. The current life expectancy beyond 70 years is a feature of the last 200 years of 
our existence. In fact, human life expectancy has been below 30 years for more than 99% of the time 
that our species has lived in this planet [64]. This means that natural selection, based on reproductive 
performance, has not fixed genetic traits assuring health after the reproductive life, precisely the period 
of high incidence of cancer. Moreover, evolution could have fixed genes which are protective in the 
early life but deleterious afterward, such as those conditioning systemic inflammation in the senescent 
immune system [64]. Long lasting immunotherapy for elderly patients with advanced cancer should Int. J. Environ. Res. Public Health 2011, 8                 
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include  therapeutic  interventions  on  the  immune-senescence  process.  Several  possibilities  are 
emerging from laboratory animal research [65], but none has moved to the clinical setting yet. 
The third is complexity. The immune system is a network of thousands of different molecules and 
cell types, interacting among themselves. Complexity means that we cannot predict the behavior of the 
system from the behavior of any of its components studied in isolation. This is a major challenge for 
the development of therapeutic combinations. Having dozens of antibodies and cancer vaccines (as it 
will be the case), represent the possibility of hundreds of different combinations and schedules, which 
are just impossible to test empirically, one by one in clinical trials. Additionally, biological molecules 
could have dual roles, being immunostimulant in some contexts and immunosuppressive in other,  
as  has  been  already  shown  for  interleukin-2  and  Granulocyte-Macrophage  Colony  Stimulating  
Factor [66,67]. A theoretical framework guiding the design of therapeutic combinations will be needed, 
but it is still not available. 
7. Conclusions: Moving from “Proof of Concept” to Impact in Public Health 
Cancer survival for all stages is improving at a population level. In the US, 5, 10 and 20-year 
survival rate estimates for all types of cancer were 63%, 57% and 51%, respectively [1]. In Europe, a 
study  of  three  million cancer  patients  diagnosed  in  the  period  1995–99,  showed  a  relative  5-year 
survival rate of 46% for men and 58% for women [68]. In Cuba, the 5-year survival rates for breast  
cancer  (female),  colon  cancer  and  prostate  cancer  have  been  estimated  in  84%,  60%  and  69%,  
respectively [8,9].  
Moreover, for some tumors, cancer survival is improving in the recurrent and disseminated stages. 
In clinical trials, small molecules and biologics have produced survival advantage in several tumors, 
and  the  low  toxicity  of  these  treatments  allows  them  to  be  used  long  term,  even  beyond  disease 
progression. New and more effective treatments for palliation and symptom control are now available.  
These data provide the preliminary evidence that advanced cancer can be transformed into a chronic 
disease, susceptible to be controlled. 
Small  molecules  and  biologics  can  become  new  and  valuable  tools  to  reinforce  the  emerging 
transition to chronicity in advanced cancer. To implement this potentiality, we need to merge the new 
tools  with  new  concepts.  In  practical  terms,  this  merging  will  demand  a  regulatory  framework 
permissive for direct testing of therapeutic combinations and for evaluation of delayed survival effects; 
the systematic re-evaluation of new treatments in population-based studies (still rarely sponsored) and 
in elder and frail patients subgroups (still rarely targeted) more representative of the real cancer patient 
population. 
There is still a long road to be walked between proof of concept and impact in population health. 
Next steps, as discussed along this review, will depend upon:  
  The acceptance of a new clinical trial paradigm (with its regulatory implications) to speed up the 
registration of new drugs, particularly for cancer immunotherapy. 
  The improvement in the manufacturing processes of biologics to guarantee wide availability and 
lower costs. Int. J. Environ. Res. Public Health 2011, 8                 
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  The training of the primary health care institutions to use biologics and small molecules for long 
term, and to evaluate their impact in the context of complex health interventions, including 
nutritional and ―quality-of-life‖ interventions. 
  The  clinical  testing  of  drug  combinations,  wisely  designed  on  the  basis  of  the  diverse 
mechanisms of action of the new drugs.  
  The output of fundamental research, providing tools to intervene in the redundant regulatory 
circuits of the immune system.  
  The identification of a simple set of meaningful tests to personalize the probability of effect of 
given small molecules or biologics in individual patients.  
  The  quality  evaluation  of  managing  advanced  cancer  at  population  level,  narrowing  the 
discrepancies between what ought to be done and what is really done. 
In  advanced  cancer,  the  road  to  chronicity  will  still  be  long,  but  there  is  already  enough 
accumulated knowledge to draw a road map.  
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